Prostate News and Research

RSS

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

7 Jul 2011

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

7 Jul 2011

Scientists identify molecular mechanism behind alcohol-induced blackouts

A person who drinks too much alcohol may be able to perform complicated tasks, such as dancing, carrying on a conversation or even driving a car, but later have no memory of those escapades. These periods of amnesia, commonly known as "blackouts," can last from a few minutes to several hours.

7 Jul 2011

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011

Medicare to cover 2 expensive cancer drugs

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer.

2 Jul 2011

First Edition: July 1, 2011

Today's early morning highlights from the major news organizations, including reports about sleep deprived medical residents, decisions by Medicare officials on covering two expensive drugs and states struggling with budget cuts.

1 Jul 2011

Novel drug delivery device can treat diabetes-related retinal damage

A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

1 Jul 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.

1 Jul 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

New prostate cancer drugs bring cost of care into spotlight

Meanwhile, results from a three-decade Swedish study found that women who have mammograms have a lower death rate from breast cancer — a finding that some say may ease recent controversies around the screening procedure.

29 Jun 2011

Some adult survivors of childhood cancer are at risk for multiple cancers

The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.

29 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

First Edition: June 28, 2011

Today's headlines include reports from the states about action on public employee benefit reforms and Planned Parenthood funding.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Prostate News and Research

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Scientists identify molecular mechanism behind alcohol-induced blackouts

New insight into tumor biology

Medicare to cover 2 expensive cancer drugs

First Edition: July 1, 2011

Novel drug delivery device can treat diabetes-related retinal damage

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

STSI joins JAX consortium to develop targeted cancer therapies

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

New prostate cancer drugs bring cost of care into spotlight

Some adult survivors of childhood cancer are at risk for multiple cancers

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

First Edition: June 28, 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News